» Articles » PMID: 38543252

Modeling Pharmacokinetics in Individual Patients Using Therapeutic Drug Monitoring and Artificial Population Quasi-Models: A Study with Piperacillin

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2024 Mar 28
PMID 38543252
Authors
Affiliations
Soon will be listed here.
Abstract

Population pharmacokinetic (pop-PK) models constructed for model-informed precision dosing often have limited utility due to the low number of patients recruited. To augment such models, an approach is presented for generating fully artificial quasi-models which can be employed to make individual estimates of pharmacokinetic parameters. Based on 72 concentrations obtained in 12 patients, one- and two-compartment pop-PK models with or without creatinine clearance as a covariate were generated for piperacillin using the nonparametric adaptive grid algorithm. Thirty quasi-models were subsequently generated for each model type, and nonparametric maximum a posteriori probability Bayesian estimates were established for each patient. A significant difference in performance was found between one- and two-compartment models. Acceptable agreement was found between predicted and observed piperacillin concentrations, and between the estimates of the random-effect pharmacokinetic variables obtained using the so-called support points of the pop-PK models or the quasi-models as priors. The mean squared errors of the predictions made using the quasi-models were similar to, or even considerably lower than those obtained when employing the pop-PK models. Conclusion: fully artificial nonparametric quasi-models can efficiently augment pop-PK models containing few support points, to make individual pharmacokinetic estimates in the clinical setting.

References
1.
Wicha S, Martson A, Nielsen E, Koch B, Friberg L, Alffenaar J . From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics. Clin Pharmacol Ther. 2021; 109(4):928-941. DOI: 10.1002/cpt.2202. View

2.
Keutzer L, You H, Farnoud A, Nyberg J, Wicha S, Maher-Edwards G . Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin. Pharmaceutics. 2022; 14(8). PMC: 9330804. DOI: 10.3390/pharmaceutics14081530. View

3.
Tatarinova T, Neely M, Bartroff J, Van Guilder M, Yamada W, Bayard D . Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn. 2013; 40(2):189-99. PMC: 3630269. DOI: 10.1007/s10928-013-9302-8. View

4.
Neely M, van Guilder M, Yamada W, Schumitzky A, Jelliffe R . Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012; 34(4):467-76. PMC: 3394880. DOI: 10.1097/FTD.0b013e31825c4ba6. View

5.
Vincze I, Czermann R, Nagy Z, Kovacs M, Neely M, Farkas R . Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin/Tazobactam and Hydrocortisone over the First Five Days of.... J Clin Med. 2022; 11(14). PMC: 9324075. DOI: 10.3390/jcm11144140. View